Allergan announces 10 presentations at American Academy of Neurology meeting

Allergan plc announced that it has 10 presentations on the schedule at the American Academy of Neurology (AAN) meeting.

The 68th annual meeting will be held April 15 to 21, in Vancouver, B.C., Canada.

"We are proud of the data being presented at AAN as it further demonstrates our leadership and commitment to research and development in neurology," Allergan EVP and president of Global R&D Brands David Nicholson said.

Allergan's presentations focus on three conditions: Alzheimer's disease, chronic migraines and limb spasticity. The results of two Phase III trials using OnabotulinumtoxinA to treat post-stroke lower limb spasticity are the subject of two presentations on April 16.

Allergan plc follows a new pharmaceutical industry model called growth pharma. The company develops and manufactures prescription, generic and over-the-counter medications and biologics, which it markets to doctors and other health care providers. Among its products are medications for conditions involving the central nervous system, eyes and women's health.

Allergan is the third largest manufacturer of generic medicines in the world. It maintains commercial operations in more than 100 countries.